MedTherapy Biotech

Executive Summary

MedTherapy Biotech is a Boston-based global CDMO founded in 2018, specializing in cell and gene therapy development and manufacturing, with a focus on CAR-T therapies and viral vectors. The company aims to reduce costs and improve accessibility of advanced therapies by offering integrated end-to-end services. It operates a technology development site in Boston and a commercial-scale GMP facility in New Delhi, India, positioning itself to serve both North American and Asian markets. With the growing demand for cell and gene therapy manufacturing capacity, MedTherapy is poised to capture market share by leveraging its dual-location strategy and cost-effective manufacturing. The company's focus on affordability and scalability aligns with industry trends toward outsourcing and global supply chain diversification.

Upcoming Catalysts (preview)

• Q3 2026Completion and GMP certification of commercial-scale facility in New Delhi70% success
• Q4 2026Announcement of strategic partnership with a major biopharma for CAR-T manufacturing50% success
• TBDRelease of next-generation viral vector platform technology40% success